Pliant Therapeutics announced it will present data from its Phase 1b FORTIFY trial of PLN-101095 at the 2026 ASCO Annual Meeting. The trial evaluates the safety and preliminary efficacy of PLN-101095, an oral dual integrin inhibitor, combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory solid tumors. This presentation highlights the ongoing development of a potential new treatment for advanced cancers resistant to current immunotherapies. Enrollment continues for patients with non-small cell lung cancer, high tumor mutational burden tumors, and clear cell renal cell carcinoma.
Fitness Champs Holdings Limited (FCHL), penyedia pendidikan olahraga air terkemuka di Singapura, akan mengadakan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) pada 29 Juni 2026, pukul 10 pagi waktu Singapura. Pemegang saham Kelas A dan Kelas B yang t...
Verizon's stock has demonstrated resilience recently compared to other telecom carriers, maintaining its status as a solid defensive investment. Despite poor performance in the last bear market, Verizon offers a strong 6% dividend yield that appears ...
Canary Capital launched the first US spot ETF for Hedera's native token HBAR, trading under ticker HBR on Nasdaq. The ETF holds actual HBAR tokens, not derivatives, with custody by BitGo and Coinbase, and charges a 0.95% fee. This fund provides tradi...
Audiera (BEAT) led crypto gainers with a 53.10% jump to $7.32, driven by increased user adoption and new partnerships in its blockchain-based music streaming platform. Other notable gainers include Provenance Blockchain, Monero, and World Liberty Fin...
AMD posted strong Q1 results with 37.8% revenue growth and a record $2.57 billion in free cash flow, reinforcing positive investor sentiment. Despite high valuation metrics, the company is expected to benefit from new AI infrastructure products shipp...
